SEC Form 3 filed by new insider Serlin Philip A
$BLRX
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 03/18/2026 | 3. Issuer Name and Ticker or Trading Symbol
BioLineRx Ltd. [ BLRX ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Ordinary Shares, 0.1 NIS per share | 5,131,800 | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Employee Stock Option (Right to Buy)(1)(2) | 10/10/2017 | 10/10/2026 | Ordinary Shares | 55,800(9) | $0.264 | D | |
| Employee Stock Option (Right to Buy)(1)(3) | 07/05/2018 | 07/05/2027 | Ordinary Shares | 316,200(9) | $0.284 | D | |
| Employee Stock Option (Right to Buy)(1)(4) | 12/26/2018 | 04/16/2028 | Ordinary Shares | 719,400(9) | $0.285 | D | |
| Employee Stock Option (Right to Buy)(1)(5) | 03/25/2020 | 11/07/2029 | Ordinary Shares | 1,136,400(9) | $0.287 | D | |
| Employee Stock Option (Right to Buy)(1)(6) | 11/17/2021 | 04/05/2031 | Ordinary Shares | 3,301,200(9) | $0.152 | D | |
| Employee Stock Option (Right to Buy)(1)(7) | 03/15/2023 | 08/15/2032 | Ordinary Shares | 4,194,600(9) | $0.102 | D | |
| Employee Stock Option (Right to Buy)(1)(8) | 03/21/2024 | 09/06/2033 | Ordinary Shares | 4,495,200(9) | $0.045 | D | |
| Explanation of Responses: |
| 1. Options granted under the 2003 Amended and Restated Share Incentive Plan. |
| 2. The grant date of this grant is October 10, 2016. This option grant is fully vested as of this date. |
| 3. The grant date of this grant is July 05 ,2017. This option grant is fully vested as of this date. |
| 4. The grant date of this grant is April 16, 2018. This option grant is fully vested as of this date. |
| 5. The grant date of this grant is November 07, 2019. This option grant is fully vested as of this date. |
| 6. The grant date of this grant is April 05, 2021. This option grant is fully vested as of this date. |
| 7. The grant date of this grant is August 15, 2022. This option grant is fully vested as of this date. |
| 8. The grant date of this grant is September 06, 2023. As of this date, 3,090,600 options of this grant are vested. The remaining 1,404,600 options will vest in equal 5 quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date. |
| 9. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee. |
| /s/ Philip Serlin | 03/18/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||